♥

Orchid Pharma Limited

ISIN : INE191A01027
NSE : ORCHPHARMA
BSE : 524372
Face Value : 10
Industry : Pharmaceuticals & Drugs

EPS : 19.06
EPS (TTM) : 23.08
Price to Earning (P/E) : 40.72
Book Value : 230.58
Price to Bookvalue (P/B) : 3.37
Dividend Yield : 0 %
Return on Equity (ROE) : 10.23 %
Return on Capital Employed (ROCE) : 9.35 %

Orchid Pharma share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	514.3 - 522.1 1.5 %
Low / High	498.85 - 526.55 5.6 %
Trade Volume	33,478
52 Week Low / High	471.3 - 898.45 90.6 %

YOU MAY ALSO LIKE

Stock market course tutorial
Stock Market Investment Course explained in simple words.
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
Share Market basics for beginners
Share Market jargons in simple terms
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR ORCHID PHARMA LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales		1309.88	1652.5	1597.6	2099.01	1829.2	1987.55	2205.91	2171.02	2444.06
Total Income		1339.19	1710.89	1686.91	2116.3	1848.05	2071.11	2282.07	2304.6	2519.77
Total Expenditure		1185.38	1474.26	1461.02	1702.13	1607.77	1754.41	1852.02	1881.84	2119.14
Other Income		29.31	58.39	89.31	17.29	18.85	83.56	76.16	133.58	75.71
Operating Profit		153.81	236.63	225.89	414.17	240.28	316.7	430.05	422.76	400.63
Interest		78.4	92.21	76.8	74.84	55.45	38.05	35.44	34.74	34.98
Exceptional Items					392.1
PBDT		75.41	144.42	149.09	731.43	184.83	278.65	394.61	388.02	365.65
Depreciation		216.29	177.64	81.81	72.12	77.08	78.41	92.69	84.2	84.44
Profit Before Tax		-140.88	-33.22	67.28	659.31	107.75	200.24	301.92	303.82	281.21
Tax									-31.19	-1.54
Profit After Tax		-140.88	-33.22	67.28	659.31	107.75	200.24	301.92	335.01	282.75
Net Profit		-140.88	-33.22	67.28	591.56	107.75	200.24	301.92	335.01	282.75
Equity Capital		408.16	408.16	408.16	408.16	507.19	507.19	507.19	507.19	507.19
Face Value (IN RS)		10	10	10	10	10	10	10	10	10
Calculated EPS		-3.68	-1.32	1.86	14.49	1.85	3.9	5.8	6.5	5.79
Diluted Eps After Extraordinary Items		-3.68	-1.32	1.86	16.15	1.85	4.3	6.18	6.81	5.79
Diluted Eps Before Extraordinary Items		-3.68	-1.32	1.86	16.15	1.85	4.3	6.18	6.81	5.79

STANDALONE QUARTERLY RESULT FOR ORCHID PHARMA LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	1802.34	1309.88	1652.5	1597.6	2099.01	1829.2	1987.55	2205.91	2171.02	2444.06
Total Income	1819.81	1339.19	1710.89	1686.91	2116.3	1848.06	2069.38	2280.27	2299.87	2521.78
Total Expenditure	1507.56	1185.38	1474.26	1461.02	1702.13	1607.78	1750.57	1846.76	1881.77	2111.58
Other Income	17.47	29.31	58.39	89.31	17.29	18.86	81.82	74.36	128.85	77.72
Operating Profit	312.25	153.81	236.63	225.89	414.17	240.28	318.81	433.51	418.1	410.2
Interest	44.59	78.4	92.21	76.8	74.84	55.45	37.98	35.37	34.47	34.73
Exceptional Items					392.1
PBDT	267.66	75.41	144.42	149.09	731.43	184.83	280.83	398.14	383.63	375.47
Depreciation	266.27	216.29	177.64	81.81	72.12	77.08	78.41	92.69	84.02	84.44
Profit Before Tax	1.39	-140.88	-33.22	67.28	659.31	107.75	202.42	305.45	299.61	291.03
Tax									-32.26
Profit After Tax	1.39	-140.88	-33.22	67.28	659.31	107.75	202.42	305.45	331.87	291.03
Net Profit	-17.81	-140.88	-33.22	67.28	648.73	107.75	202.42	305.45	331.87	291.03
Equity Capital	408.16	408.16	408.16	408.16	408.16	507.19	507.19	507.19	507.19	507.19
Face Value (IN RS)	10	10	10	10	10	10	10	10	10	10
Calculated EPS	0.03	-3.45	-0.81	1.65	16.15	2.12	3.99	6.02	6.54	5.74
Diluted Eps After Extraordinary Items	-0.44	-3.45	-0.81	1.65	16.15	2.64	4.4	6.42	6.86	5.74
Diluted Eps Before Extraordinary Items	-0.44	-3.45	-0.81	1.65	16.15	2.64	4.4	6.42	6.86	5.74

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR ORCHID PHARMA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	5595.57	6658.98	8193.68
Total Income	5685.6	6853.29	8502.31
Total Expenditure	5099.46	5822.8	7086.94
Other Income	90.03	194.31	308.63
Operating Profit	586.14	1030.49	1415.37
Interest	320.12	322.26	163.55
Exceptional Items		392.1
PBDT	266.02	1100.33	1251.82
Depreciation	870.25	547.87	332.37
Profit Before Tax	-604.23	552.46	919.45
Tax			-31.19
Profit After Tax	-604.23	552.46	950.64
Net Profit	-19.53	484.71	950.64
Equity Capital	408.16	408.16	507.19
Face Value (IN RS)	10	10	10
Reserves			11187.5
Calculated EPS	-0.48	11.35	18.17
Diluted Eps After Extraordinary Items	-0.48	13.01	19.06
Diluted Eps Before Extraordinary Items	-0.48	13.01	19.06

STANDALONE ANNUAL RESULT FOR ORCHID PHARMA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	5569.74	6658.98	8193.68
Total Income	5659.77	6853.29	8497.58
Total Expenditure	4997.15	5822.8	7086.88
Other Income	90.03	194.31	303.89
Operating Profit	662.62	1030.49	1410.7
Interest	320.12	322.26	163.28
Exceptional Items		392.1
PBDT	342.5	1100.33	1247.42
Depreciation	870.21	547.86	332.19
Profit Before Tax	-527.71	552.47	915.23
Tax			-32.26
Profit After Tax	-527.71	552.47	947.49
Net Profit	-48.08	541.89	947.49
Equity Capital	408.16	408.16	507.19
Face Value (IN RS)	10	10	10
Reserves			11676
Calculated EPS	-12.93	13.54	18.68
Diluted Eps After Extraordinary Items	-1.18	13.54	19.59
Diluted Eps Before Extraordinary Items	-1.18	13.54	19.59

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR ORCHID PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	450.06 Cr	559.56 Cr	665.9 Cr	819.37 Cr
Sales	449.6 Cr	558.78 Cr	664.85 Cr	818.07 Cr
Processing Charges / Service Income	0	0	1.05 Cr	99.44 Lk
Net Sales	450.06 Cr	559.56 Cr	665.9 Cr	819.37 Cr
Increase/Decrease in Stock	-17.09 Cr	-27.06 Cr	-21.48 Cr	-43.89 Cr
Raw Material Consumed	245.6 Cr	340.62 Cr	406.1 Cr	528.35 Cr
Opening Raw Materials	29.71 Cr	21.06 Cr	42.83 Cr	75.89 Cr
Purchases Raw Materials	252.48 Cr	362.39 Cr	439.15 Cr	518.48 Cr
Closing Raw Materials	36.59 Cr	42.83 Cr	75.89 Cr	66.01 Cr
Power & Fuel Cost	39.31 Cr	52.74 Cr	61.26 Cr	62.92 Cr
Electricity & Power	39.31 Cr	52.74 Cr	61.26 Cr	62.92 Cr
Employee Cost	67.11 Cr	63.28 Cr	65.35 Cr	69.64 Cr
Salaries, Wages & Bonus	56.39 Cr	49.36 Cr	54.5 Cr	58.92 Cr
Contributions to EPF & Pension Funds	5.02 Cr	8.49 Cr	4.25 Cr	3.94 Cr
Workmen and Staff Welfare Expenses	5.7 Cr	5.43 Cr	6.6 Cr	6.79 Cr
Other Manufacturing Expenses	29.1 Cr	32.91 Cr	35.55 Cr	39.75 Cr
Repairs and Maintenance	12.77 Cr	13.53 Cr	16.63 Cr	18.72 Cr
General and Administration Expenses	18.34 Cr	13.9 Cr	14.26 Cr	22.22 Cr
Rent , Rates & Taxes	2.78 Cr	1.41 Cr	98.59 Lk	1.59 Cr
Insurance	5.06 Cr	4.23 Cr	3.96 Cr	4.25 Cr
Printing and stationery	42.3 Lk	53.28 Lk	0	0
Professional and legal fees	7.19 Cr	4.04 Cr	4.45 Cr	3.83 Cr
Traveling and conveyance	9.77 Lk	19.7 Lk	51.21 Lk	1.11 Cr
Selling and Distribution Expenses	13.46 Cr	22.26 Cr	14.34 Cr	23.86 Cr
Advertisement & Sales Promotion	16.2 Lk	9.9 Lk	60.2 Lk	84.19 Lk
Sales Commissions & Incentives	4.05 Cr	11.53 Cr	6.75 Cr	15.98 Cr
Freight and Forwarding	9.25 Cr	10.63 Cr	6.98 Cr	7.03 Cr
Miscellaneous Expenses	24.88 Cr	6.33 Cr	6.22 Cr	5.73 Cr
Bad debts /advances written off	0	0	0	46.27 Lk
Provision for doubtful debts	1.33 Cr	3.67 Cr	1.19 Cr	0
Loss on disposal of fixed assets(net)	0	0	16.09 Lk	18.84 Lk
Total Expenditure	420.69 Cr	504.98 Cr	581.6 Cr	708.58 Cr
Other Income	15.23 Cr	9 Cr	19.43 Cr	31.13 Cr
Interest Received	73.26 Lk	41.88 Lk	61.8 Lk	16.35 Cr
Profit on sale of Fixed Assets	1.41 Lk	4,000	93.55 Lk	0
Profits on sale of Investments	1.04 Cr	51.24 Lk	1.54 Lk	0
Provision Written Back	8.57 Cr	0	0	26.51 Lk
Foreign Exchange Gains	3.49 Cr	7.58 Cr	5.2 Cr	6.73 Cr
Operating Profit	44.59 Cr	63.58 Cr	103.72 Cr	141.92 Cr
Interest	52.21 Cr	33.46 Cr	32.9 Cr	16.74 Cr
Interest on Term Loan	39.03 Cr	18.6 Cr	14.59 Cr	88.99 Lk
Bank Charges etc	87.08 Lk	1.44 Cr	67.65 Lk	38.11 Lk
PBDT	-7.61 Cr	30.13 Cr	70.82 Cr	125.18 Cr
Depreciation	108.92 Cr	87.02 Cr	54.79 Cr	33.24 Cr
Profit Before Taxation & Exceptional Items	-116.53 Cr	-56.9 Cr	16.04 Cr	91.95 Cr
Exceptional Income / Expenses	0	0	39.21 Cr	0
Profit Before Tax	-116.53 Cr	-56.9 Cr	55.25 Cr	91.95 Cr
Provision for Tax	0	0	0	-3.12 Cr
Current Income Tax	0	0	0	10.71 Lk
Deferred Tax	0	0	0	-3.23 Cr
Profit After Tax	-116.53 Cr	-56.9 Cr	55.25 Cr	95.06 Cr
Extra items	0	58.47 Cr	-6.78 Cr	0
Share of Associate	0	-3.52 Cr	-2.15 Cr	-2.9 Cr
Consolidated Net Profit	-116.53 Cr	-1.95 Cr	46.32 Cr	92.17 Cr
Profit Balance B/F	-1914.24 Cr	-2313.84 Cr	-2314.33 Cr	-2268.24 Cr
Appropriations	-2030.77 Cr	-2315.79 Cr	-2268.01 Cr	-2176.07 Cr
Other Appropriation	-59.85 Lk	-1.46 Cr	23.28 Lk	45.06 Lk
Earnings Per Share	-28.55	-0.48	11.35	18.17
Adjusted EPS	-28.55	-0.48	11.35	18.17

STANDALONE PROFIT / LOSS FOR ORCHID PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	450.7 Cr	556.97 Cr	665.9 Cr	819.37 Cr
Sales	450.23 Cr	556.2 Cr	664.85 Cr	818.07 Cr
Processing Charges / Service Income	0	77.28 Lk	1.05 Cr	99.44 Lk
Net Sales	450.7 Cr	556.97 Cr	665.9 Cr	819.37 Cr
Increase/Decrease in Stock	-15.69 Cr	-22.73 Cr	-21.48 Cr	-43.89 Cr
Raw Material Consumed	244.96 Cr	336.8 Cr	406.1 Cr	528.35 Cr
Opening Raw Materials	29.71 Cr	21.06 Cr	42.83 Cr	75.89 Cr
Purchases Raw Materials	236.31 Cr	358.57 Cr	439.15 Cr	518.48 Cr
Closing Raw Materials	21.06 Cr	42.83 Cr	75.89 Cr	66.01 Cr
Power & Fuel Cost	39.31 Cr	52.74 Cr	61.26 Cr	62.92 Cr
Electricity & Power	39.31 Cr	52.74 Cr	61.26 Cr	62.92 Cr
Employee Cost	64.4 Cr	60.21 Cr	65.35 Cr	69.64 Cr
Salaries, Wages & Bonus	53.68 Cr	49.36 Cr	54.5 Cr	58.92 Cr
Contributions to EPF & Pension Funds	5.02 Cr	5.42 Cr	4.25 Cr	3.94 Cr
Workmen and Staff Welfare Expenses	5.7 Cr	5.43 Cr	6.6 Cr	6.79 Cr
Other Manufacturing Expenses	29.09 Cr	32.91 Cr	35.55 Cr	39.75 Cr
Repairs and Maintenance	12.77 Cr	13.53 Cr	16.63 Cr	18.72 Cr
General and Administration Expenses	15.23 Cr	11.67 Cr	14.26 Cr	22.22 Cr
Rent , Rates & Taxes	2.01 Cr	70.45 Lk	98.59 Lk	1.59 Cr
Insurance	4.53 Cr	3.75 Cr	3.96 Cr	4.25 Cr
Printing and stationery	42.3 Lk	53.28 Lk	0	0
Professional and legal fees	5.41 Cr	3 Cr	4.45 Cr	3.83 Cr
Traveling and conveyance	9.77 Lk	19.7 Lk	51.21 Lk	1.11 Cr
Selling and Distribution Expenses	11.52 Cr	20.35 Cr	14.34 Cr	23.86 Cr
Advertisement & Sales Promotion	8.63 Lk	9.9 Lk	60.2 Lk	84.19 Lk
Sales Commissions & Incentives	3.48 Cr	10.71 Cr	6.75 Cr	15.98 Cr
Freight and Forwarding	7.96 Cr	9.54 Cr	6.98 Cr	7.03 Cr
Miscellaneous Expenses	24.39 Cr	6.32 Cr	6.22 Cr	5.72 Cr
Bad debts /advances written off	0	0	0	46.27 Lk
Provision for doubtful debts	1.33 Cr	3.67 Cr	1.19 Cr	0
Loss on disposal of fixed assets(net)	0	0	16.09 Lk	18.84 Lk
Total Expenditure	413.22 Cr	498.27 Cr	581.6 Cr	708.57 Cr
Other Income	6.48 Cr	9 Cr	19.43 Cr	30.65 Cr
Interest Received	73.26 Lk	41.88 Lk	61.8 Lk	15.87 Cr
Profit on sale of Fixed Assets	1.41 Lk	4,000	93.55 Lk	0
Profits on sale of Investments	1.04 Cr	51.24 Lk	1.54 Lk	0
Provision Written Back	0	0	0	26.51 Lk
Foreign Exchange Gains	3.31 Cr	7.58 Cr	5.2 Cr	6.73 Cr
Operating Profit	43.95 Cr	67.71 Cr	103.72 Cr	141.45 Cr
Interest	52.21 Cr	33.46 Cr	32.9 Cr	16.71 Cr
Interest on Term Loan	39.03 Cr	18.6 Cr	14.59 Cr	88.99 Lk
Bank Charges etc	87.11 Lk	1.44 Cr	67.65 Lk	38.11 Lk
PBDT	-8.25 Cr	34.25 Cr	70.82 Cr	124.74 Cr
Depreciation	108.9 Cr	87.02 Cr	54.79 Cr	33.22 Cr
Profit Before Taxation & Exceptional Items	-117.15 Cr	-52.77 Cr	16.04 Cr	91.52 Cr
Exceptional Income / Expenses	0	0	39.21 Cr	0
Profit Before Tax	-117.15 Cr	-52.77 Cr	55.25 Cr	91.52 Cr
Provision for Tax	0	0	0	-3.23 Cr
Deferred Tax	0	0	0	-3.23 Cr
Profit After Tax	-117.15 Cr	-52.77 Cr	55.25 Cr	94.75 Cr
Extra items	0	47.96 Cr	-1.06 Cr	0
Consolidated Net Profit	-117.15 Cr	-4.81 Cr	54.19 Cr	94.75 Cr
Profit Balance B/F	-2016.74 Cr	-2133.29 Cr	-2136.64 Cr	-2082.68 Cr
Appropriations	-2133.89 Cr	-2138.1 Cr	-2082.45 Cr	-1987.93 Cr
Other Appropriation	-59.85 Lk	-1.46 Cr	23.28 Lk	45.06 Lk
Earnings Per Share	-28.7	-12.93	13.54	18.68
Adjusted EPS	-28.7	-12.93	13.54	18.68

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR ORCHID PHARMA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	-116.53 Cr	-1.95 Cr	46.32 Cr	89.05 Cr
Adjustment	172.15 Cr	36.77 Cr	51.38 Cr	44.15 Cr
Changes In working Capital	-36.96 Cr	59.57 Cr	-79.06 Cr	-7.84 Cr
Cash Flow after changes in Working Capital	18.66 Cr	94.38 Cr	18.64 Cr	125.36 Cr
Cash Flow from Operating Activities	23.59 Cr	92.47 Cr	18.34 Cr	125.99 Cr
Cash Flow from Investing Activities	67.21 Cr	112.94 Cr	-31.21 Cr	-312.03 Cr
Cash Flow from Financing Activitie	-164.99 Cr	-216.8 Cr	31.17 Cr	167.04 Cr
Net Cash Inflow / Outflow	-74.2 Cr	-11.39 Cr	18.29 Cr	-19 Cr
Opening Cash & Cash Equivalents	89.89 Cr	15.69 Cr	4.31 Cr	22.6 Cr
Closing Cash & Cash Equivalent	15.69 Cr	4.31 Cr	22.6 Cr	3.6 Cr

STANDALONE CASH FLOW FOR ORCHID PHARMA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	-117.15 Cr	-4.81 Cr	54.19 Cr	91.52 Cr
Adjustment	163.69 Cr	38.24 Cr	54.1 Cr	41.68 Cr
Changes In working Capital	-27.1 Cr	58.04 Cr	-94.6 Cr	-3.22 Cr
Cash Flow after changes in Working Capital	19.44 Cr	91.47 Cr	13.69 Cr	129.99 Cr
Cash Flow from Operating Activities	24.36 Cr	89.57 Cr	13.39 Cr	130.73 Cr
Cash Flow from Investing Activities	67.21 Cr	112.93 Cr	-26.7 Cr	-315.81 Cr
Cash Flow from Financing Activitie	-164.99 Cr	-216.8 Cr	31.17 Cr	167.07 Cr
Net Cash Inflow / Outflow	-73.42 Cr	-14.3 Cr	17.86 Cr	-18.01 Cr
Opening Cash & Cash Equivalents	88.17 Cr	14.75 Cr	45.02 Lk	18.31 Cr
Closing Cash & Cash Equivalent	14.75 Cr	45.02 Lk	18.31 Cr	29.47 Lk

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR ORCHID PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	40.82 Cr	40.82 Cr	40.82 Cr	50.72 Cr
Equity - Authorised	150 Cr	150.1 Cr	150.1 Cr	150.1 Cr
Equity - Issued	40.82 Cr	40.82 Cr	40.82 Cr	50.72 Cr
Equity Paid Up	40.82 Cr	40.82 Cr	40.82 Cr	50.72 Cr
Face Value	10	10	10	10
Total Reserves	612.09 Cr	606.56 Cr	647.83 Cr	1118.75 Cr
Securities Premium	464.48 Cr	464.48 Cr	464.48 Cr	846.52 Cr
Capital Reserves	1682.31 Cr	1682.31 Cr	1682.31 Cr	1682.31 Cr
Profit & Loss Account Balance	-2030.17 Cr	-2314.33 Cr	-2268.24 Cr	-2176.52 Cr
General Reserves	558.52 Cr	558.52 Cr	558.52 Cr	558.52 Cr
Reserve excluding Revaluation Reserve	612.09 Cr	606.56 Cr	647.83 Cr	1118.75 Cr
Shareholder's Funds	652.91 Cr	647.38 Cr	688.65 Cr	1169.47 Cr
Secured Loans	341.6 Cr	110.84 Cr	40.09 Cr	22.07 Lk
Term Loans - Banks	364 Cr	147.79 Cr	81.64 Cr	22.07 Lk
Unsecured Loans	85.9 Cr	97.32 Cr	108.75 Cr	120.21 Cr
Deferred Tax Assets / Liabilities	3.23 Cr	3.23 Cr	3.23 Cr	0
Deferred Tax Assets	149.34 Cr	82.83 Cr	86.11 Cr	110.81 Cr
Deferred Tax Liability	152.57 Cr	86.06 Cr	89.33 Cr	110.81 Cr
Other Long Term Liabilities	0	0	0	37 Lk
Long Term Provisions	11.54 Cr	11.01 Cr	12.6 Cr	3.63 Cr
Total Non-Current Liabilities	442.26 Cr	222.4 Cr	164.67 Cr	124.43 Cr
Trade Payables	109.95 Cr	167.68 Cr	181.78 Cr	229.58 Cr
Sundry Creditors	109.95 Cr	167.68 Cr	181.78 Cr	229.58 Cr
Other Current Liabilities	25.76 Cr	47.25 Cr	45.67 Cr	14.27 Cr
Advances received from customers	0	0	0	1.95 Cr
Short Term Borrowings	2.84 Cr	22.84 Cr	140.95 Cr	14.05 Cr
Secured ST Loans repayable on Demands	2.84 Cr	22.84 Cr	140.95 Cr	14.05 Cr
Working Capital Loans- Sec	2.84 Cr	22.84 Cr	140.95 Cr	14.05 Cr
Short Term Provisions	3.52 Cr	3.01 Cr	3.49 Cr	2.08 Cr
Total Current Liabilities	142.08 Cr	240.78 Cr	371.89 Cr	259.97 Cr
Total Liabilities	1237.25 Cr	1110.56 Cr	1225.21 Cr	1553.87 Cr
Gross Block	1176.1 Cr	1176.39 Cr	1220.56 Cr	1300.94 Cr
Less: Accumulated Depreciation	505.66 Cr	592.68 Cr	647.47 Cr	680.71 Cr
Net Block	670.44 Cr	583.7 Cr	573.09 Cr	620.23 Cr
Capital Work in Progress	7.43 Cr	9.78 Cr	46.46 Cr	16.39 Cr
Non Current Investments	40.44 Lk	45.49 Cr	44.44 Cr	45.82 Cr
Long Term Investment	40.44 Lk	45.49 Cr	44.44 Cr	45.82 Cr
Quoted	12.62 Lk	8.53 Lk	13.93 Lk	25.27 Lk
Unquoted	87.82 Lk	46.01 Cr	44.9 Cr	46.17 Cr
Long Term Loans & Advances	9.1 Cr	21.69 Cr	60.2 Cr	66.38 Cr
Other Non Current Assets	1.33 Lk	74,000	0	1.58 Lk
Total Non-Current Assets	687.4 Cr	660.68 Cr	724.2 Cr	763.12 Cr
Currents Investments	15.02 Cr	0	0	0
Unquoted	87.82 Lk	46.01 Cr	44.9 Cr	46.17 Cr
Inventories	152.88 Cr	172.66 Cr	228.74 Cr	264.23 Cr
Raw Materials	36.59 Cr	42.83 Cr	75.89 Cr	66.01 Cr
Work-in Progress	55.56 Cr	69.08 Cr	77.45 Cr	114.87 Cr
Finished Goods	53.81 Cr	54.84 Cr	67.95 Cr	74.42 Cr
Packing Materials	3.47 Cr	2.36 Cr	3.99 Cr	2.9 Cr
Stores and Spare	3.45 Cr	3.54 Cr	3.46 Cr	6.03 Cr
Sundry Debtors	135.7 Cr	170.57 Cr	215.19 Cr	195.55 Cr
Debtors more than Six months	0	12.94 Cr	0	49.86 Cr
Debtors Others	202.92 Cr	238.58 Cr	258.94 Cr	189.16 Cr
Cash and Bank	19.91 Cr	8.06 Cr	30.63 Cr	266.56 Cr
Cash in hand	4.36 Lk	3.46 Lk	66,000	4.32 Lk
Balances at Bank	19.87 Cr	8.03 Cr	30.62 Cr	266.52 Cr
Other Current Assets	130.48 Cr	26.3 Cr	3.95 Cr	7.02 Cr
Interest accrued on Investments	0	14,000	15.84 Lk	4.5 Cr
Interest accrued and or due on loans	7.07 Lk	0	0	0
Prepaid Expenses	2.57 Cr	7.12 Cr	3.79 Cr	2.22 Cr
Short Term Loans and Advances	95.87 Cr	72.3 Cr	22.5 Cr	57.39 Cr
Advances recoverable in cash or in kind	6.1 Cr	3.47 Cr	9.64 Cr	10.51 Cr
Advance income tax and TDS	54.46 Cr	52.55 Cr	95.37 Lk	1.64 Cr
Total Current Assets	549.86 Cr	449.89 Cr	501.01 Cr	790.75 Cr
Net Current Assets (Including Current Investments)	407.78 Cr	209.11 Cr	129.12 Cr	530.78 Cr
Total Assets	1237.25 Cr	1110.56 Cr	1225.21 Cr	1553.87 Cr
Contingent Liabilities	45.12 Cr	24.87 Cr	41.95 Cr	56.97 Cr
Total Debt	452.74 Cr	267.95 Cr	331.35 Cr	134.48 Cr
Book Value	159.96	158.61	168.72	230.58
Adjusted Book Value	159.96	158.61	168.72	230.58

STANDALONE BALANCE SHEET FOR ORCHID PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	40.82 Cr	40.82 Cr	40.82 Cr	50.72 Cr
Equity - Authorised	150 Cr	150.1 Cr	150.1 Cr	150.1 Cr
Equity - Issued	40.82 Cr	40.82 Cr	40.82 Cr	50.72 Cr
Equity Paid Up	40.82 Cr	40.82 Cr	40.82 Cr	50.72 Cr
Face Value	10	10	10	10
Total Reserves	640.52 Cr	637.14 Cr	691.15 Cr	1167.6 Cr
Securities Premium	464.48 Cr	464.48 Cr	464.48 Cr	846.52 Cr
Capital Reserves	1682.31 Cr	1682.31 Cr	1682.31 Cr	1682.31 Cr
Profit & Loss Account Balance	-2133.29 Cr	-2136.64 Cr	-2082.68 Cr	-1988.38 Cr
General Reserves	558.52 Cr	558.52 Cr	558.52 Cr	558.52 Cr
Reserve excluding Revaluation Reserve	640.52 Cr	637.14 Cr	691.15 Cr	1167.6 Cr
Shareholder's Funds	681.34 Cr	677.95 Cr	731.96 Cr	1218.32 Cr
Secured Loans	341.6 Cr	110.84 Cr	40.09 Cr	0
Term Loans - Banks	364 Cr	147.79 Cr	81.64 Cr	0
Unsecured Loans	85.9 Cr	97.32 Cr	108.75 Cr	120.21 Cr
Deferred Tax Assets / Liabilities	3.23 Cr	3.23 Cr	3.23 Cr	0
Deferred Tax Assets	149.34 Cr	82.83 Cr	86.11 Cr	110.81 Cr
Deferred Tax Liability	152.57 Cr	86.06 Cr	89.33 Cr	110.81 Cr
Other Long Term Liabilities	0	0	0	37 Lk
Long Term Provisions	11.54 Cr	11.01 Cr	12.6 Cr	3.63 Cr
Total Non-Current Liabilities	442.26 Cr	222.4 Cr	164.67 Cr	124.21 Cr
Trade Payables	68.74 Cr	120.74 Cr	136.52 Cr	179.39 Cr
Sundry Creditors	68.74 Cr	120.74 Cr	136.52 Cr	179.39 Cr
Other Current Liabilities	25.76 Cr	47.25 Cr	45.67 Cr	14.15 Cr
Advances received from customers	0	0	0	1.95 Cr
Short Term Borrowings	2.84 Cr	22.84 Cr	140.95 Cr	14.05 Cr
Secured ST Loans repayable on Demands	2.84 Cr	22.84 Cr	140.95 Cr	14.05 Cr
Working Capital Loans- Sec	2.84 Cr	22.84 Cr	140.95 Cr	14.05 Cr
Short Term Provisions	3.52 Cr	3.01 Cr	3.49 Cr	2.08 Cr
Total Current Liabilities	100.87 Cr	193.83 Cr	326.63 Cr	209.67 Cr
Total Liabilities	1224.47 Cr	1094.19 Cr	1223.26 Cr	1552.2 Cr
Gross Block	1175.97 Cr	1176.26 Cr	1220.45 Cr	1297.02 Cr
Less: Accumulated Depreciation	505.58 Cr	592.6 Cr	647.39 Cr	680.59 Cr
Net Block	670.39 Cr	583.65 Cr	573.06 Cr	616.43 Cr
Capital Work in Progress	7.43 Cr	9.78 Cr	46.09 Cr	10.18 Cr
Non Current Investments	40.44 Lk	49.01 Cr	50.12 Cr	69.4 Cr
Long Term Investment	40.44 Lk	49.01 Cr	50.12 Cr	69.4 Cr
Quoted	12.62 Lk	8.53 Lk	13.93 Lk	25.27 Lk
Unquoted	125.04 Cr	173.69 Cr	174.68 Cr	193.85 Cr
Long Term Loans & Advances	3.98 Cr	16.42 Cr	60.2 Cr	59.61 Cr
Other Non Current Assets	1.33 Lk	74,000	0	1.58 Lk
Total Non-Current Assets	682.22 Cr	658.88 Cr	729.46 Cr	769.91 Cr
Currents Investments	15.02 Cr	0	0	0
Unquoted	125.04 Cr	173.69 Cr	174.68 Cr	193.85 Cr
Inventories	150.57 Cr	172.66 Cr	228.74 Cr	264.23 Cr
Raw Materials	36.59 Cr	42.83 Cr	75.89 Cr	66.01 Cr
Work-in Progress	55.56 Cr	69.08 Cr	77.45 Cr	114.87 Cr
Finished Goods	51.49 Cr	54.84 Cr	67.95 Cr	74.42 Cr
Packing Materials	3.47 Cr	2.36 Cr	3.99 Cr	2.9 Cr
Stores and Spare	3.45 Cr	3.54 Cr	3.46 Cr	6.03 Cr
Sundry Debtors	131.96 Cr	160.23 Cr	211.91 Cr	189.37 Cr
Debtors more than Six months	0	2.6 Cr	82.14 Cr	82.08 Cr
Debtors Others	199.18 Cr	238.58 Cr	211.91 Cr	189.16 Cr
Cash and Bank	18.97 Cr	4.21 Cr	22.34 Cr	257.23 Cr
Cash in hand	4.36 Lk	3.46 Lk	66,000	1.82 Lk
Balances at Bank	18.92 Cr	4.17 Cr	22.33 Cr	257.21 Cr
Other Current Assets	130.11 Cr	26.15 Cr	3.64 Cr	6.8 Cr
Interest accrued on Investments	0	14,000	13,000	4.35 Cr
Interest accrued and or due on loans	7.07 Lk	0	0	0
Prepaid Expenses	2.2 Cr	6.98 Cr	3.64 Cr	2.15 Cr
Short Term Loans and Advances	95.63 Cr	72.06 Cr	27.17 Cr	64.67 Cr
Advances recoverable in cash or in kind	5.99 Cr	3.36 Cr	9.64 Cr	10.51 Cr
Advance income tax and TDS	54.46 Cr	52.55 Cr	95.37 Lk	1.69 Cr
Total Current Assets	542.25 Cr	435.31 Cr	493.79 Cr	782.29 Cr
Net Current Assets (Including Current Investments)	441.38 Cr	241.48 Cr	167.16 Cr	572.62 Cr
Total Assets	1224.47 Cr	1094.19 Cr	1223.26 Cr	1552.2 Cr
Contingent Liabilities	45.12 Cr	24.87 Cr	38.16 Cr	49.17 Cr
Total Debt	452.74 Cr	267.95 Cr	331.35 Cr	134.26 Cr
Book Value	166.93	166.1	179.33	240.21
Adjusted Book Value	166.93	166.1	179.33	240.21

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR ORCHID PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	-28.55	-0.48	11.35	18.17
CEPS(Rs)	-1.87	7.38	26.96	25.3
Book NAV/Share(Rs)	159.96	158.61	168.72	230.58
Tax Rate(%)	0	0	0	-3.39
Margin Ratios
Core EBITDA Margin(%)	6.53	9.75	12.66	13.52
EBIT Margin(%)	-14.29	-4.19	13.24	13.26
Pre Tax Margin(%)	-25.89	-10.17	8.3	11.22
PAT Margin (%)	-25.89	-10.17	8.3	11.6
Cash Profit Margin (%)	-1.69	5.38	16.52	15.66
Performance Ratios
ROA(%)	-8.64	-4.85	4.73	6.84
ROE(%)	-16.43	-8.75	8.27	10.23
ROCE(%)	-5.28	-2.32	9.11	9.35
Asset Turnover(x)	0.33	0.48	0.57	0.59
Sales/Fixed Asset(x)	0.37	0.48	0.56	0.65
Working Capital/Sales(x)	1.1	2.68	5.16	1.54
Efficiency Ratios
Fixed Capital/Sales(x)	2.69	2.1	1.8	1.54
Receivable days	82.59	99.89	105.72	91.49
Inventory Days	119.45	106.18	110.01	109.8
Payable days	77.23	161.59	165.82	152.17
Valuation Parameters
PER(x)	0	0	33.87	57.52
PCE(x)	-1321.56	38.52	14.26	41.32
Price/Book(x)	15.41	1.79	2.28	4.53
EV/Net Sales(x)	23.32	2.54	2.81	6.31
EV/Core EBITDA(x)	235.35	22.34	18.03	36.42
EV/EBIT(x)	-163.15	-60.59	21.21	47.56
EV/CE(x)	8.48	1.28	1.53	3.96
M Cap / Sales	22.36	2.07	2.36	6.47
Growth Ratio
Net Sales Growth(%)	-6.97	24.33	19	23.05
Core EBITDA Growth(%)	745.09	-3.48	63.14	36.82
EBIT Growth(%)	48.48	45.54	476.02	23.29
PAT Growth(%)	11.09	40.26	197.1	72.07
EPS Growth(%)	11.09	98.33	2473.84	60.13
Financial Stability Ratios
Total Debt/Equity(x)	0.69	0.41	0.48	0.12
Current Ratio(x)	3.87	1.87	1.35	3.04
Quick Ratio(x)	2.79	1.15	0.73	2.03
Interest Cover(x)	-1.23	-0.7	2.68	6.49
Total Debt/Mcap(x)	0.04	0.23	0.21	0.03

FINANCIAL RATIOS (STANDALONE) FOR ORCHID PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	-28.7	-12.93	13.54	18.68
CEPS(Rs)	-2.02	8.39	26.96	25.23
Book NAV/Share(Rs)	166.93	166.1	179.33	240.21
Tax Rate(%)	0	0	0	-3.53
Margin Ratios
Core EBITDA Margin(%)	8.32	10.54	12.66	13.52
EBIT Margin(%)	-14.41	-3.47	13.24	13.21
Pre Tax Margin(%)	-25.99	-9.47	8.3	11.17
PAT Margin (%)	-25.99	-9.47	8.3	11.56
Cash Profit Margin (%)	-1.83	6.15	16.52	15.62
Performance Ratios
ROA(%)	-8.76	-4.55	4.77	6.83
ROE(%)	-15.84	-7.76	7.84	9.72
ROCE(%)	-5.2	-1.86	8.77	8.96
Asset Turnover(x)	0.34	0.48	0.57	0.59
Sales/Fixed Asset(x)	0.37	0.47	0.56	0.65
Working Capital/Sales(x)	1.02	2.31	3.98	1.43
Efficiency Ratios
Fixed Capital/Sales(x)	2.69	2.11	1.8	1.54
Receivable days	80.31	95.74	101.99	89.38
Inventory Days	117.98	105.91	110.01	109.8
Payable days	47.63	110.1	122.07	116.21
Valuation Parameters
PER(x)	0	0	28.4	55.95
PCE(x)	-1218.92	33.88	14.26	41.43
Price/Book(x)	14.77	1.71	2.14	4.35
EV/Net Sales(x)	23.29	2.56	2.82	6.32
EV/Core EBITDA(x)	238.8	21.03	18.11	36.61
EV/EBIT(x)	-161.6	-73.74	21.3	47.84
EV/CE(x)	8.57	1.3	1.54	3.83
M Cap / Sales	22.33	2.08	2.36	6.47
Growth Ratio
Net Sales Growth(%)	-6.34	23.58	19.56	23.05
Core EBITDA Growth(%)	270.99	3.79	53.2	36.37
EBIT Growth(%)	54.78	55.77	556.39	22.78
PAT Growth(%)	21.81	44.96	204.69	71.5
EPS Growth(%)	21.81	44.96	204.69	38.02
Financial Stability Ratios
Total Debt/Equity(x)	0.66	0.4	0.45	0.11
Current Ratio(x)	5.38	2.25	1.51	3.73
Quick Ratio(x)	3.88	1.36	0.81	2.47
Interest Cover(x)	-1.24	-0.58	2.68	6.48
Total Debt/Mcap(x)	0.04	0.23	0.21	0.03

SHARE HOLDING PATTERN FOR ORCHID PHARMA LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	89.96	89.96	89.96	89.96	72.40	72.40	69.84	69.84	69.84	69.84
FII %	1.48	1.37	0.86	0.81	0.45	8.08	4.14	1.96	1.42	1.94
DII %	0.00	0.00	1.20	0.00	3.53	2.58	1.54	1.50	1.04	0.59
Public %	5.55	5.68	5.23	6.60	5.53	7.06	11.53	10.47	9.81	9.93

PEER COMPARISON FOR ORCHID PHARMA LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR ORCHID PHARMA

Exchange Date	Purpose	Book Closure Dates
BSE 06-Aug-2024	Board Meeting - Quarterly Results	12-Aug-2024
BSE 16-May-2024	Board Meeting - Audited Results	23-May-2024
BSE 02-Feb-2024	Board Meeting - Quarterly Results	08-Feb-2024
BSE 30-Oct-2023	Board Meeting - Quarterly Results	04-Nov-2023
BSE 04-Aug-2023	Board Meeting - Quarterly Results	10-Aug-2023
BSE 13-Jul-2023	Book Closure - A.G.M.	03-Aug-2023 09-Aug-2023
BSE 13-Jul-2023	AGM - A.G.M.	09-Aug-2023 09-Aug-2023
BSE 03-May-2023	Board Meeting - Audited Results	10-May-2023
BSE 03-Feb-2023	Board Meeting - Quarterly Results	09-Feb-2023
BSE 05-Dec-2022	Book Closure - E.G.M.	23-Dec-2022 29-Dec-2022
BSE 28-Nov-2022	Board Meeting - Inter alia, to consider and approve, amongst other things, raising of funds and issuance of securities through Qualified Institutions Placement basis or through any other permissible mode, in one or more tranches, subject to applicable laws and necessary approval from the shareholders and other regulatory authorities, as may be required.	01-Dec-2022
BSE 07-Nov-2022	Board Meeting - Quarterly Results	14-Nov-2022
BSE 01-Aug-2022	Board Meeting - Quarterly Results	10-Aug-2022
BSE 22-Jun-2022	Book Closure - A.G.M.	08-Jul-2022 15-Jul-2022
BSE 22-Jun-2022	AGM - A.G.M.	15-Jul-2022 15-Jul-2022
BSE 05-May-2022	Board Meeting - Audited Results	12-May-2022
BSE 07-Feb-2022	Board Meeting - Quarterly Results	12-Feb-2022
BSE 08-Nov-2021	Board Meeting - Quarterly Results	14-Nov-2021

CORPORATE ANNOUNCEMENTS FOR ORCHID PHARMA

Exchange Date	Category File	Description
BSE 14-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulations 2018 for the quarter-II of the F.Y. 2024-25 ended on September 30 2024.
BSE 27-Sep-2024	General Announcements FILE	Intimation Related To The Scheme Of Amalgamation Of DhanukaLaboratories Limited ('Amalgamating Company') With Orchid Pharma Limited ('Amalgamated Company') And Their Respective Shareholders And Creditors ('The Scheme') Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 '(SEBI Listing Regulations)' As Amended. Intimation related to the Scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited under Regulation 30 SEBI (LODR) Regulations 2015
BSE 27-Sep-2024	General Announcements FILE	Intimation Of Email Received From BSE For Warning Letter Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Intimation of email received from BSE for Warning Letter under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
BSE 26-Sep-2024	General Announcements FILE	Email Received From NSE Regarding Warning Letter Under SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR ) Intimation of Warning Letter received from NSE under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
BSE 25-Sep-2024	Intimation FILE	Closure of Trading Window Intimation of Trading Window Closure of the Company for the Quarter II/ Half year of Financial Year 2024-25 ending on September 30 2024
BSE 11-Sep-2024	General Announcements FILE	Investor Roadshow Scheduled To Be Held On September 18 2024 Intimation of Investor Road Show scheduled to be held on September 18 2024 by Orchid Pharma Limited
BSE 03-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Scheme of Arrangement Intimation for receipt of Observation/No-Objection Letters from BSE Limited and National Stock Exchange of India Limited in relation to the Scheme of Amalgamation of Dhanuka Laboratories Limited and Orchid Pharma Limited with their respective shareholders and creditors
BSE 22-Aug-2024	General Announcements FILE	Disclosure Regarding The Order Passed By Goods And Service Tax Department Disclosure regarding the Order passed by Goods and Service Tax Department
BSE 22-Aug-2024	General Announcements FILE	Chairman Speech- 31St Annual General Meeting Of Orchid Pharma Limited Held On August 21 2024 Chairman Speech delivered at 31st Annual General Meeting of Orchid Pharma Limited
BSE 21-Aug-2024	General Announcements FILE	Voting Results For The 31St Annual General Meeting Of Orchid Pharma Limited Voting Results for the 31st Annual General Meeting of Orchid Pharma Limited
BSE 21-Aug-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Scritinizer Report for the 31st Annual General Meeting of Orchid Pharma Limited
BSE 21-Aug-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM Summary of Proceedings of 31st Annual General Meeting of Orchid Pharma Limited held on August 21 2024
BSE 17-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Earnings Call Transcript Transcript of Analysts/ Investors Earning Call for the Financial Results of the Company for the Quarter- 1 of Financial Year 2024-25 ended on June 30 2024.
BSE 14-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Publication of Un-Audited Standalone and Consolidated Financial Results for Quarter-1 of Financial Year 2024-25 ended on June 30 2024
BSE 14-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Orchid Pharma continues to be on a steady and strong growth trajectory
BSE 13-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Audio Recording of the Analysts/Investors Earnings Call of Orchid Pharma Limited for the Financial Results of Quarter-1 of Financial Year-2024-25 ended on June 30 2024
BSE 13-Aug-2024	General Announcements FILE	Monitoring Agency Report Of The Company For The Quarter-1 Of Financial Year 2024-25 Ended On June 30 2024 Monitoring Agency Report of the Company for the Quarter-1 of Financial Year 2024-25 ended on June 30 2024
BSE 13-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Investor Presentation Investor Presentation for Analysts/ Earnings Call for Quarter-1 of F.Y.2024-25 ended on June 30 2024
BSE 12-Aug-2024	Compliance FILE	Statement Of Deviation And Variation For Qtr Ended June 2024 Statement with NIL deviation and variation for the qtr ended June 2024.
BSE 12-Aug-2024	Outcome FILE	Board Meeting Outcome for Financial Results For June 2024 Outcome of Board Meeting held on August 12 2024
BSE 12-Aug-2024	Outcome FILE	Financial Results For The Qtr June 2024 Financial Results for the quarter ended June 2024
BSE 07-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Orchid Pharma Limited has scheduled an Analysts/ Investors Earning Call for the Quarter-1 of financial year 2024-25 ended on June 30 2024.
BSE 06-Aug-2024	Intimation FILE	Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On August 12 2024 Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve Unaudited Limited Reviewed Financial Results (Standalone &Consolidated) of the Company for the Quarter-1 of financial year 2024-25 ended on June 30 2024
BSE 28-Jul-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Publication for dispatching the Notice of 31st Annual General Meeting along with the Annual Report for F.Y.2023-24 of Orchid Pharma Limited
BSE 27-Jul-2024	General Announcements FILE	Business Responsibility and Sustainability Reporting (BRSR) Business Responsibility and Sustainability Report of Orchid Pharma Limited for the Financial Year 2023-24
BSE 27-Jul-2024	Intimation FILE	Notice Of 31St Annual General Meeting Of Orchid Pharma Limited For The Financial Year 2023-24 Notice of 31st Annual General Meetings of Orchid Pharma Limited for the Financial Year 2023-24
BSE 27-Jul-2024	General Announcements FILE	Reg. 34 (1) Annual Report. Annual Report inter-alia including the Financial Statements Report of Board of Directors and Notice of 31st Annual General Meeting of Orchid Pharma Limited (the Company) for the Financial Year 2023-24
BSE 25-Jul-2024	General Announcements FILE	Update On The Cut-Off Date For E-Voting W.R.T. The Ensuing 31St Annual General Meeting Of Orchid Pharma Limited ('The Company') On August 21 2024 Update on the cut-off date from August 12 2024 to August 14 2024 for e-voting w.r.t. the ensuing 31st 31st Annual General Meeting to be held on August 21 2024
BSE 23-Jul-2024	General Announcements FILE	Newspaper Publication For Information Regarding 31St Annual General Meeting Of Orchid Pharma Limited Newspaper Publication for Information regarding 31st Annual General Meeting of Orchid Pharma Limited
BSE 19-Jul-2024	Outcome FILE	Board Meeting Outcome for Outcome Of The Adjourned Board Meeting Held On July 19 2024 Considered and approved the Board Report and annexures thereto for the F.Y.2023-24 and Notice of the AGM to be held on August 21 2024.

INSIDER TRADING FOR ORCHID PHARMA

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 28-Nov-2023 28-Nov-2023	Sell Off Market	1,300,000 @ 0.00 (2.56 %)	DHANUKA LABORATORIES LTD

BULK BLOCK DEALS FOR ORCHID PHARMA LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 28-Nov-2023	Sell BULK	1,300,000 @ 571.28	DHANUKA LABORATORIES LIMITED
BSE 28-Nov-2023	Buy BULK	445,000 @ 571.00	UTI MUTUAL FUND

DIVIDEND BY ORCHID PHARMA LIMITED

No dividend details found

SPLIT / BONUS BY ORCHID PHARMA LIMITED

No Split / Bonus details found

Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed

Facebook

Twitter

To TOP

Orchid Pharma Limited

Orchid Pharma share price

CONSOLIDATED QUARTERLY RESULT FOR ORCHID PHARMA LIMITED

STANDALONE QUARTERLY RESULT FOR ORCHID PHARMA LIMITED

CONSOLIDATED ANNUAL RESULT FOR ORCHID PHARMA LIMITED

STANDALONE ANNUAL RESULT FOR ORCHID PHARMA LIMITED

CONSOLIDATED PROFIT / LOSS FOR ORCHID PHARMA LIMITED

STANDALONE PROFIT / LOSS FOR ORCHID PHARMA LIMITED

CONSOLIDATED CASH FLOW FOR ORCHID PHARMA LIMITED

STANDALONE CASH FLOW FOR ORCHID PHARMA LIMITED

CONSOLIDATED BALANCE SHEET FOR ORCHID PHARMA LIMITED

STANDALONE BALANCE SHEET FOR ORCHID PHARMA LIMITED

FINANCIAL RATIOS (CONSOLIDATED) FOR ORCHID PHARMA LIMITED

FINANCIAL RATIOS (STANDALONE) FOR ORCHID PHARMA LIMITED

SHARE HOLDING PATTERN FOR ORCHID PHARMA LIMITED

PEER COMPARISON FOR ORCHID PHARMA LIMITED

CORPORATE ACTIONS FOR ORCHID PHARMA

CORPORATE ANNOUNCEMENTS FOR ORCHID PHARMA

INSIDER TRADING FOR ORCHID PHARMA

BULK BLOCK DEALS FOR ORCHID PHARMA LIMITED

DIVIDEND BY ORCHID PHARMA LIMITED

SPLIT / BONUS BY ORCHID PHARMA LIMITED